Turnover at pharmaceutical and biotech product development consultancy Boyds has surged by 25% as demand for its specialist services continues to grow.
The company has added seven regulatory and medical affairs experts to its team, and is now launching an even larger recruitment drive creating up to ten new roles to enhance its expertise, service demand for its services, and expand the business. Boyds has partnered with UK specialist recruitment company CK Clinical to oversee the drive.
Over the past 12 months, Boyds’ regulatory team has worked with the MHRA in the UK and with the EU and US regulatory authorities on 19 orphan drug designations, 11 scientific advice procedures and three investigational new drug (IND) applications.
The company has been directly involved in supporting seven of the ten gene-based therapies that are now available for patient use either in the UK, the EU or the US. In 2018, it was awarded the Queen’s Award for Enterprise in recognition of this international work.
“Our team of experts works with biotechs, academic groups and pharma companies from the early pre-clinical stages all the way through clinical development, products approval and beyond,” said Professor Alan Boyd, who started the company 16 years ago. “We have experienced significant year-on-year growth with an increased demand particularly for our expertise in advanced therapy medicinal products (ATMPs) and gene therapies, a trend that is continuing.’’
